S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
EWTX · Edgewise Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Edgewise Therapeutics Inc (EWTX)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$39.65
-0.09
(-0.23%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$39.65
$39.45
$40.70
52-WEEK RANGE
$39.65
$14.68
$48.51
What's happening
- EWTX is down 0.23% today, trading at $39.65. — Live quote
- Volume today (51,408) is well below its 3-month average of 1,443,410. (Finnhub fundamentals)
- Reports earnings on 2026-11-04, 13 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.53 actual vs. $-0.48 estimated (-10.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 7
Buy 9
Hold 3
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (19 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
EWTX
+59.78%
vs S&P 500
+46.41%
1-YEAR RETURN
EWTX
+155.64%
vs S&P 500
+140.48%
6-MONTH RETURN
EWTX
+15.16%
3-MONTH RETURN
EWTX
+3.44%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.53
Est. $-0.48
MISS -10.6%
2026-04-26 (Q1 2026)
$-0.46
Est. $-0.50
BEAT +7.3%
2026-01-26 (Q4 2025)
$-0.47
Est. $-0.44
MISS -5.7%
2025-10-26 (Q3 2025)
$-0.39
Est. $-0.41
BEAT +3.8%
Valuation Measures & Ratios
Enterprise Value4$4.23B
Forward P/E5—
PEG Ratio6-1.14
Price / Sales (TTM1)—
Price / Book79.76
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-39.01%
Return on Assets (ROA9)-36.96%
Avg Volume (3M)1,443,410
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $4.39B | $3.36B | $1.69B | $1.39B | $2.09B |
| P/E | -24.00 | -20.14 | -11.15 | -9.77 | -15.47 |
| Price/Book | 9.81 | 6.80 | 3.03 | 2.36 | 4.86 |
| ROE | -40.87% | -33.78% | -27.16% | -24.20% | -31.40% |
| ROA | -38.18% | -32.13% | -26.00% | -23.24% | -29.70% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short11,224,347
Change from Prior Settlement+17.61%
% of Float—
Days to Cover (Short Ratio)5.60
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +155.6%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-10-02; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on EWTX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$61.9M | -$54.1M | -$46.9M | -$42.6M | -$46.0M | -$40.4M | -$38.1M | -$34.8M |
| Net income | -$57.3M | -$49.0M | -$40.7M | -$36.1M | -$40.8M | -$34.1M | -$31.5M | -$28.5M |
| EPS (diluted) | $-0.53 | $-0.46 | $-0.39 | $-0.34 | $-0.43 | $-0.36 | $-0.34 | $-0.33 |
| EPS (basic) | $-0.53 | $-0.46 | $-0.39 | $-0.34 | $-0.43 | $-0.36 | $-0.34 | $-0.33 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $479.7M | $518.5M | $552.6M | $583.5M | $613.3M | $454.4M | $486.8M | $511.3M |
| Total liabilities | $31.6M | $25.3M | $30.3M | $24.8M | $24.3M | $24.7M | $27.6M | $22.4M |
| Stockholders' equity | $448.1M | $493.2M | $522.3M | $558.6M | $589.1M | $429.7M | $459.2M | $488.9M |
| Total current assets | $471.5M | $509.8M | $543.4M | $573.9M | $603.3M | $443.2M | $475.5M | $499.4M |
| Total current liabilities | $29.0M | $22.5M | $27.4M | $21.6M | $20.9M | $21.1M | $23.9M | $19.0M |
| Cash & equivalents | $72.3M | $33.2M | $61.1M | $46.0M | $43.4M | $49.9M | $41.7M | $44.8M |
| Property, plant & equipment | $6.9M | $7.4M | $7.8M | $8.1M | $8.6M | $9.0M | $9.5M | $10.0M |
| Other non-current assets | — | — | — | — | — | $695.0K | $262.0K | $262.0K |
| Accounts payable | $4.7M | $7.3M | $6.0M | $6.2M | $8.3M | $8.8M | $5.6M | $5.6M |
| Accrued liabilities | $5.2M | $8.6M | $7.9M | $6.5M | $5.9M | $7.4M | $7.2M | $6.1M |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $10.0K | $10.0K | $10.0K | $10.0K | $10.0K | $9.0K | $9.0K | $9.0K |
| Retained earnings | -$652.7M | -$595.4M | -$546.4M | -$496.2M | -$455.5M | -$419.4M | -$378.6M | -$338.9M |
| Accumulated other comprehensive income (loss) | -$500.0K | -$252.0K | $677.0K | $701.0K | $204.0K | $401.0K | $420.0K | $1.1M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$42.5M | -$42.5M | -$38.6M | -$34.8M | -$32.6M | -$37.9M | -$27.0M | -$27.4M |
| Investing cash flow | $78.5M | $2.4M | $49.8M | $35.7M | -$162.2M | $43.9M | $20.9M | $25.4M |
| Financing cash flow | $3.1M | $12.2M | $4.0M | $1.7M | $188.2M | $2.2M | $2.9M | $3.3M |
| Free cash flow | -$42.5M | -$42.8M | -$38.7M | -$34.9M | -$32.6M | -$37.9M | -$27.2M | -$27.9M |
| Capital expenditures | $32.0K | $260.0K | $73.0K | $89.0K | $50.0K | $44.0K | $274.0K | $520.0K |
| Share-based compensation | $9.4M | $8.7M | $9.9M | $8.1M | $7.7M | $9.1M | $7.7M | $6.9M |
| Change in accounts payable | $781.0K | $1.4M | -$303.0K | -$2.1M | -$151.0K | $2.9M | $92.0K | -$1.0M |
| Purchases of investments | $53.1M | $110.2M | $74.3M | $67.0M | $263.8M | $122.2M | $63.2M | $45.3M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$191.4M | -$158.8M | -$114.4M | -$71.7M | -$43.2M |
| Net income | -$167.8M | -$133.8M | -$100.2M | -$67.6M | -$42.8M |
| EPS (diluted) | $-1.63 | $-1.45 | $-1.57 | $-1.26 | $-1.14 |
| EPS (basic) | $-1.63 | $-1.45 | $-1.57 | $-1.26 | $-1.14 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $552.6M | $486.8M | $340.0M | $367.1M | $285.2M |
| Total liabilities | $30.3M | $27.6M | $21.2M | $20.4M | $10.8M |
| Stockholders' equity | $522.3M | $459.2M | $318.8M | $346.7M | $274.4M |
| Total current assets | $543.4M | $475.5M | $327.0M | $357.0M | $283.8M |
| Total current liabilities | $27.4M | $23.9M | $16.8M | $16.6M | $10.5M |
| Cash & equivalents | $61.1M | $41.7M | $86.1M | $22.0M | $15.6M |
| Property, plant & equipment | $7.8M | $9.5M | $10.4M | $8.5M | $912.0K |
| Other non-current assets | — | $262.0K | $348.0K | $251.0K | $548.0K |
| Accounts payable | $6.0M | $5.6M | $4.0M | $6.1M | $3.8M |
| Accrued liabilities | $7.9M | $7.2M | $6.1M | $5.8M | $3.9M |
| Other non-current liabilities | — | — | — | — | $329.0K |
| Common stock & paid-in capital | $10.0K | $9.0K | $7.0K | $6.0K | $5.0K |
| Retained earnings | -$546.4M | -$378.6M | -$244.8M | -$144.6M | -$77.0M |
| Accumulated other comprehensive income (loss) | $677.0K | $420.0K | $99.0K | -$1.4M | -$514.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$143.8M | -$109.0M | -$91.9M | -$52.6M | -$33.5M |
| Investing cash flow | -$32.8M | -$184.7M | $102.9M | -$70.6M | -$242.2M |
| Financing cash flow | $196.1M | $249.3M | $53.2M | $129.6M | $186.4M |
| Free cash flow | -$144.1M | -$110.3M | -$97.7M | -$58.2M | -$34.2M |
| Capital expenditures | $256.0K | $1.3M | $5.7M | $5.5M | $668.0K |
| Share-based compensation | $34.8M | $24.7M | $17.6M | $10.9M | $4.4M |
| Change in accounts payable | $272.0K | $1.7M | -$92.0K | $47.0K | $2.7M |
| Purchases of investments | $527.2M | $477.1M | $255.9M | $292.4M | $288.2M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding EWTX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-11-12 to 2026-10-01
Recent transactions
- Insiders have net sold 298,659 shares over the last 182 days, across 0 purchases and 23 sales.
- Most recent: Fox Jonathan C (Reporting person) — Grant / award of 308 shares on 2026-10-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)298,659 sh(23 txns)
Net Shares-298,659
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Fox Jonathan C | Reporting person | Grant / award | 2026-10-01 | 308 |
| Donovan Joanne M. | CMO | Open market sale | 2026-08-13 | 2,919 |
| Russell Alan J | Chief Scientific Officer | Option exercise | 2026-08-12 | 5,781 |
| MOORE JOHN R | General Counsel | Option exercise | 2026-08-12 | 5,781 |
| Derakhshan Behrad | Chief Business Officer | Option exercise | 2026-08-12 | 5,781 |
| KOCH KEVIN | President and CEO | Option exercise | 2026-08-12 | 17,969 |
| Edris Badreddin | Reporting person | Option exercise | 2026-01-21 | 13,690 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | Fox Jonathan C | Reporting person | Grant / award | 308 | $0.00 |
| 2026-08-13 | Donovan Joanne M. | CMO | Open market sale | 2,919 | $43.41 |
| 2026-08-12 | Donovan Joanne M. | CMO | Option exercise | 5,781 | $0.00 |
| 2026-08-12 | Donovan Joanne M. | CMO | Option exercise | 7,031 | $0.00 |
| 2026-08-12 | Donovan Joanne M. | CMO | Open market sale | 2,839 | $43.78 |
| 2026-08-12 | Donovan Joanne M. | CMO | Open market sale | 2,779 | $43.71 |
| 2026-08-12 | Donovan Joanne M. | CMO | Open market sale | 104 | $44.43 |
| 2026-08-12 | Donovan Joanne M. | CMO | Open market sale | 800 | $44.52 |
| 2026-08-12 | Russell Alan J | Chief Scientific Officer | Option exercise | 5,781 | $0.00 |
| 2026-08-12 | Russell Alan J | Chief Scientific Officer | Option exercise | 7,031 | $0.00 |
| 2026-08-12 | Russell Alan J | Chief Scientific Officer | Open market sale | 3,238 | $43.68 |
| 2026-08-12 | Russell Alan J | Chief Scientific Officer | Open market sale | 2,273 | $43.68 |
| 2026-08-12 | Russell Alan J | Chief Scientific Officer | Open market sale | 390 | $44.46 |
| 2026-08-12 | MOORE JOHN R | General Counsel | Option exercise | 5,781 | $0.00 |
| 2026-08-12 | MOORE JOHN R | General Counsel | Option exercise | 6,718 | $0.00 |
| 2026-08-12 | MOORE JOHN R | General Counsel | Open market sale | 2,439 | $43.81 |
| 2026-08-12 | MOORE JOHN R | General Counsel | Open market sale | 59 | $44.41 |
| 2026-08-12 | MOORE JOHN R | General Counsel | Open market sale | 99 | $44.50 |
| 2026-08-12 | MOORE JOHN R | General Counsel | Open market sale | 2,419 | $43.80 |
| 2026-08-12 | Derakhshan Behrad | Chief Business Officer | Option exercise | 5,781 | $0.00 |
| 2026-08-12 | Derakhshan Behrad | Chief Business Officer | Option exercise | 7,500 | $0.00 |
| 2026-08-12 | Derakhshan Behrad | Chief Business Officer | Open market sale | 2,171 | $43.79 |
| 2026-08-12 | Derakhshan Behrad | Chief Business Officer | Open market sale | 304 | $44.50 |
| 2026-08-12 | Derakhshan Behrad | Chief Business Officer | Open market sale | 150 | $44.44 |
| 2026-08-12 | Derakhshan Behrad | Chief Business Officer | Open market sale | 2,475 | $43.70 |
| 2026-08-12 | KOCH KEVIN | President and CEO | Option exercise | 17,969 | $0.00 |
| 2026-08-12 | KOCH KEVIN | President and CEO | Option exercise | 21,875 | $0.00 |
| 2026-08-12 | KOCH KEVIN | President and CEO | Open market sale | 8,782 | $43.64 |
| 2026-08-12 | KOCH KEVIN | President and CEO | Open market sale | 8,276 | $43.66 |
| 2026-08-12 | KOCH KEVIN | President and CEO | Open market sale | 913 | $44.33 |
| 2026-07-01 | Russell Alan J | Chief Scientific Officer | Option exercise | 130,352 | $0.45 |
| 2026-07-01 | Russell Alan J | Chief Scientific Officer | Option exercise | 69,648 | $0.18 |
| 2026-07-01 | Russell Alan J | Chief Scientific Officer | Open market sale | 130,352 | $39.41 |
| 2026-07-01 | Russell Alan J | Chief Scientific Officer | Open market sale | 69,648 | $39.41 |
| 2026-07-01 | Fox Jonathan C | Reporting person | Grant / award | 319 | $0.00 |
| 2026-05-05 | Donovan Joanne M. | CMO | Option exercise | 50,000 | $7.08 |
| 2026-05-05 | Donovan Joanne M. | CMO | Open market sale | 50,000 | $38.57 |
| 2026-05-04 | Donovan Joanne M. | CMO | Open market sale | 5,230 | $31.29 |
| 2026-04-01 | Fox Jonathan C | Reporting person | Grant / award | 339 | $0.00 |
| 2026-04-01 | Donovan Joanne M. | CMO | Option exercise | 28,662 | $7.08 |
| 2026-04-01 | Donovan Joanne M. | CMO | Open market sale | 28,662 | $32.31 |
| 2026-03-31 | Donovan Joanne M. | CMO | Option exercise | 21,338 | $7.08 |
| 2026-03-31 | Donovan Joanne M. | CMO | Open market sale | 21,338 | $32.12 |
| 2026-03-27 | Donovan Joanne M. | CMO | Open market sale | 9,623 | $30.98 |
| 2026-03-27 | Donovan Joanne M. | CMO | Open market sale | 6,735 | $30.98 |
| 2026-01-21 | Edris Badreddin | Reporting person | Option exercise | 13,690 | $0.39 |
| 2026-01-21 | Edris Badreddin | Reporting person | Option exercise | 17,236 | $0.64 |
| 2026-01-21 | Edris Badreddin | Reporting person | Option exercise | 10,463 | $1.93 |
| 2026-01-21 | Edris Badreddin | Reporting person | Option exercise | 66,477 | $1.93 |
| 2026-01-21 | Edris Badreddin | Reporting person | Option exercise | 7,605 | $0.71 |
| 2026-01-21 | Edris Badreddin | Reporting person | Open market sale | 13,690 | $29.44 |
| 2026-01-21 | Edris Badreddin | Reporting person | Open market sale | 17,236 | $29.44 |
| 2026-01-21 | Edris Badreddin | Reporting person | Open market sale | 7,605 | $29.44 |
| 2026-01-21 | Edris Badreddin | Reporting person | Open market sale | 10,463 | $29.44 |
| 2026-01-21 | Edris Badreddin | Reporting person | Open market sale | 66,477 | $29.44 |
| 2026-01-02 | Fox Jonathan C | Reporting person | Grant / award | 473 | $0.00 |
| 2025-11-12 | Russell Alan J | Chief Scientific Officer | Option exercise | 100,000 | $0.18 |
| 2025-11-12 | Russell Alan J | Chief Scientific Officer | Open market sale | 100,000 | $21.12 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 05:14 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-08-14 | 4 | 2026-08-12 | View on SEC.gov → |
| 2026-08-14 | 4 | 2026-08-12 | View on SEC.gov → |
| 2026-08-14 | 4 | 2026-08-12 | View on SEC.gov → |
| 2026-08-14 | 4 | 2026-08-12 | View on SEC.gov → |
| 2026-08-14 | 4 | 2026-08-12 | View on SEC.gov → |
| 2026-08-14 | 4 | 2026-08-12 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-17 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-07-13 | 8-K | 2026-07-10 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
Recent news
Headlines about EWTX (Edgewise Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
Yahoo Finance · 2026-10-21 -
Edgewise Therapeutics, Inc. (EWTX) stock price, news, quote and history
Yahoo Finance UK · 2026-10-20 -
EWTX Nov 2026 47.000 call (EWTX261120C00047000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
EWTX Nov 2026 39.000 put (EWTX261120P00039000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?
Yahoo Finance · 2026-10-19 -
EWTX Nov 2026 46.000 call (EWTX261120C00046000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-18 -
EWTX Nov 2026 46.000 call (EWTX261120C00046000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-18 -
EWTX Oct 2026 36.000 put (EWTX261016P00036000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-17
No headlines in this category right now — try “All”.